Press Room


    Press Release - January 08, 2007

    Award Winning Harvard Diabetes Specialist Appointed to Help Advance Sernova's Sertolin Diabetes Therapy to Clinical Trials

    Kelowna, B.C. - Sernova Corp. ("Sernova") is pleased to announce that Dr. George King, Senior Vice President and Director of Research at Harvard Medical School's Joslin Diabetes Center, has accepted an appointment to Sernova's Scientific Advisory Board.

    One of the world's foremost diabetolgists, Dr. King has an extensive and successful history of conducting research into the causes, complications and treatment options of diabetes. Dr. David White, principal researcher for Sernova states, "With such an intricate understanding of the biology of diabetes, Dr. King will be an excellent advisor for our preclinical studies and be of great assistance during our application process to the FDA and other health regulators."

    Dr. King commented, "This is a promising cellular therapy for treating diabetes so I look forward to assisting Sernova to advance the technology. Being an emerging technology, xenotransplantation needs to proceed with meticulous attention to accepted medical and research practises and I believe Sernova will follow these protocols closely."

    About Dr. King

    Dr. King received his medical degree from Duke University Medical School, completed residency training at the University of Washington Affiliated Hospitals in Seattle, and then completed research training at the National Institutes of Health in Bethesda Maryland. He has been at the Joslin Clinic and Harvard Medical School since 1981. He is currently the Director of Research and Head of the Section on Vascular Cell Biology at Joslin, and a Professor of Medicine at Harvard Medical School.

    Dr. King has received numerous awards including the Donald Silver Excellence in Research Award from the Juvenile Diabetes Foundation, the Cogan Award from the Association for Research in Vision and Ophthalmology, the Stadie Memorial Award and Lectureship from the Philadelphia Affiliate of the American Diabetes Association, the Alcon Award for Vision Research, and the Annual Award for Excellence in Research from the Japan Society of Diabetic Complications.

    About Sernova

    Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

    ON BEHALF OF THE BOARD "Justin Leushner" -------------------------- Justin Leushner, President

    For further information contact: Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493



    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News